pharma · Familial adenomatous polyposis (FAP) · Familial Adenomatous Polyposis · BDRX
Biodexa Pharmaceuticals
Biodexa Pharmaceuticals Plc
Biodexa Pharmaceuticals is a pharma organization headquartered in cardiff, GB. It trades on NYSE under ticker BDRX. Primary therapeutic focus areas include Familial adenomatous polyposis (FAP), Familial Adenomatous Polyp
cardiff, GB HQ
2000 Founded
25 Employees
Public company Type
BDRX · NYSE Ticker
Company details
- Status
- Public
- HQ
- cardiff, GB
- Founded
- 2000
- Employees
- 25
- Programs
- 4
- Drugs
- 5
- Patents
- 2
eRapa (encapsulated rapamycin)
Phase 3 · small molecule · Familial Adenomatous Polyposis (FAP)
eRapa (encapsulated rapamycin) for Familial Adenomatous Polyposis (FAP) is a Phase 3 program (small_molecule) at Biodexa Pharmaceuticals Plc with 1 ClinicalTrials.gov record(s).
Internal code MTX230-301
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Biodexa Pharmaceuticals Plc
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Familial Adenomatous Polyposis (FAP)
- Status
- active
- Trials
- 1